Gene Therapy for Alzheimer's Disease
Gene therapy with wild-type PS1 and PS2 encoding polynucleotides addresses the impairment of gamma-secretase activity caused by presenilin gene mutations, offering a potential treatment for Alzheimer's disease by restoring normal function and reducing amyloid beta protein accumulation.
Patent Information
- Application Number
- JP2020565341
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-05-22
- Filing Date
- 2019-05-22
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2039-05-22
AI Technical Summary
Current treatments for Alzheimer's disease are ineffective, and mutations in the presenilin genes, PSEN1 and PSEN2, contribute to the pathogenesis of Alzheimer's by impairing gamma-secretase activity, leading to amyloid beta protein accumulation.
Gene therapy using polynucleotides encoding wild-type PS1 and/or PS2 proteins, delivered via vectors like AAV, to restore normal gamma-secretase activity and function in the brain, targeting neuronal cells to treat Alzheimer's disease and other neurodegenerative conditions.
The method effectively increases wild-type PS1 or PS2 expression, reversing gamma-secretase dysfunction and potentially slowing or halting the progression of Alzheimer's disease by reducing amyloid beta protein accumulation.
Smart Images

Figure 0007587423000016 
Figure 0007587423000017 
Figure 0007587423000018
Abstract
Description
[Technical field]
[0001] Claiming priority This application claims the benefit of U.S. Provisional Application No. 62 / 675,003, filed May 22, 2018, the entire contents of which are incorporated herein by reference.
[0002] Federally Sponsored Research or Development This invention was made with Government support under Grant Nos. NS041783 and NS075346 awarded by the National Institutes of Health. The Government has certain rights in this invention.
[0003] Among other things, described herein are compositions and methods for treating Alzheimer's disease (AD) and other neurodegenerative diseases using presenilin gene therapy constructs. [Background technology]
[0004] Alzheimer's disease, also known as Alzheimer's disease, accounts for the majority of neurodegenerative dementias and is the fourth leading cause of death in the United States, behind heart disease, cancer and stroke. It is characterized by progressive loss of cognitive function, neurodegeneration, neurofibrillary tangles and amyloid plaques in patients' brains. The rate of progression varies from patient to patient, but the average life expectancy after diagnosis is 3-9 years. Currently, there is no cure for Alzheimer's disease. Summary of the Invention
[0005] Described herein is a novel approach that can be used to treat subjects with Alzheimer's disease (AD) and other neurodegenerative diseases, disorders or conditions. Mutations in the presenilin genes, PSEN1 and PSEN2, are highly penetrant and account for approximately 90% of all identified mutations in familial AD (FAD), highlighting their importance in the pathogenesis of AD. More than 260 separate mutations have been reported in PSEN1, which are dominantly inherited and mostly missense mutations. Pathogenic PSEN1 mutations act in cis to impair mutant PS1 function and in trans to inhibit wild-type presenilin 1 (PS1) function (Heilig et al. J Neurosci 33:11606-717 (2013); Zhou et al. Proc Natl Acad Sci USA 114:12731-12736 (2017)). Typically, due to these very properties, dominant-negative mutations cannot be restored by expression of wild-type protein (Herskowitz, I. Nature, 329:219-222 (1987)). The present disclosure is based, at least in part, on the unexpected discovery that feeding wild-type PSEN1 cDNA to immortalized MEFs carrying heterozygous or homozygous dominant-negative Psen1 mutations, a well-established model of familial Alzheimer's disease, restored impaired gamma-secretase activity in such cells. Dominant-negative mutations in PSEN1 and PSEN2 genes are known to be associated with early-onset familial Alzheimer's disease. It is generally believed that PS1 and presenilin 2 (PS2) proteins are part of the gamma-secretase complex, and mutations in PSEN1 and PSEN2 genes contribute to the accumulation of amyloid beta (Aβ) protein in Alzheimer's disease patients. Thus, the present disclosure provides methods for effective gene therapy for Alzheimer's disease and other neurodegenerative dementias based on PSEN1 (due to PS1 expression) and / or PSEN2 (due to PS2 expression), representing a major breakthrough in this disease area.
[0006] In a first aspect, provided herein is a method for treating a neurodegenerative disease, disorder or condition, comprising administering to a subject in need of treatment a polynucleotide comprising PSEN1 and / or PSEN2 gene or mRNA, e.g., encoding PS1 or PS2 protein, as described herein. In some embodiments, the neurodegenerative disease, disorder or condition is Alzheimer's disease, e.g., familial Alzheimer's disease, characterized by one or more mutations in PSEN1 and / or PSEN2 genes. In some embodiments, the Alzheimer's disease is sporadic Alzheimer's disease. In some embodiments, the Alzheimer's disease is late-onset or early-onset Alzheimer's disease. In some embodiments, the neurodegenerative disease, disorder or condition is frontotemporal dementia, frontotemporal lobar degeneration, Pick's disease, or Lewy body dementia. In some embodiments, the neurodegenerative disease, disorder or condition is memory loss. In some embodiments, the neurodegenerative disease, disorder or condition is cognitive decline or impairment. In some embodiments, the cognitive impairment is mild cognitive impairment (MCI). In some embodiments, the polynucleotide is a vector, for example a viral vector.
[0007] Also provided herein is a polynucleotide sequence encoding a PS1 and / or PS2 protein or a therapeutically active fragment thereof, optionally in a vector, wherein the polynucleotide sequence encoding PS1 and / or PS2 is operably linked to a promoter that causes expression of PS1 and / or PS2 in the brain. Also provided herein is the use of the polynucleotide sequences and vectors for use in the treatment of the neurodegenerative diseases, disorders or conditions described herein.
[0008] In some embodiments, the viral vector is an adeno-associated viral (AAV) vector. In some embodiments, the AAV vector is selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO, AAV11, AAV12, AAV2 / 1, AAV2 / 2, AAV2 / 5, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV2 / 9, AAV2 / rhlO, AAV2 / AAV11 or AAV2 / AAV12.
[0009] In some embodiments, the viral vector is a lentiviral vector or a retroviral vector.
[0010] In some embodiments, the polynucleotide encodes the presenilin 1 (PSEN1) gene or mRNA. In some embodiments, the polynucleotide encodes the presenilin 2 (PSEN2) gene or mRNA. In some embodiments, the polynucleotide encodes the presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes or mRNA.
[0011] In some embodiments, the polynucleotide sequence encodes a PS1 protein, e.g., PSEN1 mRNA, and comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of wild-type human presenilin 1 transcript variant 1 mRNA (SEQ ID NO:1) or the sequence of wild-type human presenilin 1 transcript variant 2 mRNA (SEQ ID NO:2).
[0012] In some embodiments, the polynucleotide sequence encodes a PS2 protein, e.g., PSEN2 mRNA, and comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of wild-type human presenilin 2 transcript variant 1 mRNA (SEQ ID NO:1) or the sequence of wild-type human presenilin 2 transcript variant 2 mRNA (SEQ ID NO:2).
[0013] In some embodiments, a polynucleotide sequence encoding a PS1 and / or PS2 protein, eg, a presenilin 1 (PSEN1) and / or presenilin 2 (PSEN2) gene or mRNA, is operably linked to a promoter.
[0014] In some embodiments, the promoter is a pan-neuronal promoter. In some embodiments, the pan-neuronal promoter is a synapsin I promoter. In some embodiments, the pan-neuronal promoter is a 1.6 kb hybrid promoter consisting of the CMV immediate early enhancer and CBA intron 1 / exon 1 (commonly referred to as the "CAGGS promoter").
[0015] In some embodiments, the promoter is a neuronal subtype-specific promoter, for example, the alpha-calcium / calmodulin kinase 2A promoter.
[0016] In some embodiments, the promoter is a cytomegalovirus (CMV) early enhancer / promoter, a hybrid CMV enhancer / chicken beta actin (CBA) promoter, or a promoter containing the CMV early enhancer element, the first exon and first intron of the chicken beta actin gene, and the splice acceptor site of the rabbit beta globulin gene (commonly referred to as the "CAG promoter").
[0017] In some embodiments, a polynucleotide sequence encoding a PS1 and / or PS2 protein, eg, a PSEN1 and / or PSEN2 gene or mRNA, is administered to the CNS of a subject in need of treatment.
[0018] In some embodiments, a polynucleotide encoding a PS1 and / or PS2 protein, e.g., a PSEN1 and / or PSEN2 gene or mRNA, is administered to the CNS by intravenous delivery, intrathecal delivery, intraventricular administration, stereotactic intraparenchymal administration, intracisternal administration, intraventricular delivery, or stereotactic injection(s) into specific brain regions, e.g., the cisterna magna, ventricles, lumbar intrathecal cavity, direct injection into the hippocampus and / or neocortex.
[0019] In some embodiments, the polynucleotide is associated with (e.g., formulated for delivery using) an exosome, or a lipid-based nanoparticle (LNP).
[0020] Also provided herein is the use of the vector described herein for treating a neurodegenerative disease, disorder or condition described herein. In some embodiments, the neurodegenerative disease, disorder or condition is Alzheimer's disease. In some embodiments, the Alzheimer's disease is familial Alzheimer's disease. In some embodiments, the Alzheimer's disease is sporadic Alzheimer's disease. In some embodiments, the Alzheimer's disease is late-onset Alzheimer's disease. In some embodiments, the neurodegenerative disease, disorder or condition is frontotemporal dementia, frontotemporal lobar degeneration, Pick's disease, or Lewy body dementia. In some embodiments, the neurodegenerative disease, disorder or condition is memory loss. In some embodiments, the neurodegenerative disease, disorder or condition is cognitive decline or cognitive impairment. In some embodiments, the cognitive impairment is mild cognitive impairment (MCI).
[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Methods and materials are described herein for use in the present invention, and other suitable methods and materials known in the art can also be used.Materials, methods, and examples are merely illustrative and are not intended to be limiting.All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety.In case of conflict, the present specification, including definitions, will control.
[0022] Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims. [Brief description of the drawings]
[0023] [Figure 1A-B] Figure 1. Decreased levels of mRNAs encoding PS1 and PSEN2 in hippocampal pyramidal neurons of sporadic AD brains. A, Representative images of human hippocampal CA1 pyramidal neurons before (top) and after (bottom) laser capture microdissection (LCM). B, Quantitative RT-PCR analysis shows approximately 30% reduction in PS1, PSEN2, Nicastrin (Nct) mRNA in CA1 pyramidal neurons of sporadic AD brains (n=9, Braak stage III / IV) compared to control brains with normal cognition (n=8). PS1, PSEN2, Nicastrin (Nct) and Pen2 mRNA levels were normalized to RPLP0 mRNA, a ubiquitously expressed ribosomal mRNA, and values for mRNA from control brains were set as 100%. All data are expressed as mean ± SEM. Statistical analysis was performed using unpaired two-tailed Student's t-test. *p<0.05; **p<0.01; NS, not significant. [Figure 2A-B]Figure 1. Reduced gamma-secretase activity in Psen1 KI / +, KI / KI and Psen1- / - cells. In A, Western blotting using cell lysates from immortalized MEFs derived from embryos carrying various Psen1 genotypes shows reduced gamma-secretase activity in PS1 L435F KI / +, KI / KI and PS1- / - cells as indicated by reduced NICD production. MEFs were transfected with 1.25 μg Hes1-Luc and 5 ng Notch-ΔE. Antibodies specific for PS1, NICD and the N-terminus of α-tubulin were used. In B, quantification of NICD (left graph) and PS1-NTF (right graph) levels is shown. Protein levels were normalized to α-tubulin and protein levels in + / + cells are represented as 100%. All data are presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test. *p<0.05; **p<0.01; ***p<0.001 compared to + / + cells. [Figure 3A] Figure 1: Introduction of WT hPS1 restores impaired γ-secretase activity in mutant MEFs. In A, γ-secretase activity measured by NICD production is reduced in mutant MEF cells in a PS dose-dependent manner (WT>PS1 heterozygous KI or KO>homozygous PS1 KI or KO>DKO). In B, impaired γ-secretase activity is restored by WT hPS1. Increasing amounts of pCI-hPS1 plasmid DNA are transfected into MEFs of different genotypes as indicated. Western analysis showed that both PS1 NTFs and NICD are restored in various PS mutant MEFs. Heterozygous L435F KI cells are labeled as KI / + or PS1L435F / +. N=3 independent experiments. Data represent mean ± SEM. *p<0.05; **p<0.01; ***p<0.001 (one-way ANOVA with Tukey's post-hoc test analysis). [Figure 3B]Figure 1: Introduction of WT hPS1 restores impaired γ-secretase activity in mutant MEFs. In A, γ-secretase activity measured by NICD production is reduced in mutant MEF cells in a PS dose-dependent manner (WT>PS1 heterozygous KI or KO>homozygous PS1 KI or KO>DKO). In B, impaired γ-secretase activity is restored by WT hPS1. Increasing amounts of pCI-hPS1 plasmid DNA are transfected into MEFs of different genotypes as indicated. Western analysis showed that both PS1 NTFs and NICD are restored in various PS mutant MEFs. Heterozygous L435F KI cells are labeled as KI / + or PS1L435F / +. N=3 independent experiments. Data represent mean ± SEM. *p<0.05; **p<0.01; ***p<0.001 (one-way ANOVA with Tukey's post-hoc test analysis). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] definition In order that this disclosure may be more readily understood, certain terms are first defined as follows: Further definitions of the following terms, as well as other terms, are set forth throughout the specification.
[0025] Dosage: As used herein, the term "administration" refers to the delivery or application of a composition to a subject or system. Administration to an animal subject (e.g., human) can be by any suitable route. For example, in some embodiments, administration can be bronchial (including by bronchial instillation), buccal, enteral, intercutaneous, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, intranasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, intravaginal and intravitreal administration.
[0026] Biologically active: As used herein, the phrase "biologically active" refers to the property of any substance that has activity in a biological system (e.g., a cell culture, an organism, etc.). For example, a substance that has a biological effect on an organism when administered to the organism is considered to be biologically active. Biological activity can also be determined by in vitro assays (e.g., in vitro enzyme assays). In certain embodiments, if a protein or polypeptide is biologically active, a portion of the protein or polypeptide that shares at least one biological activity of the protein or polypeptide is typically referred to as a "biologically active" portion. In some embodiments, the protein is produced and / or purified from a cell culture system that exhibits biological activity when administered to a subject.
[0027] Control: As used herein, the term "control" has its art-understood meaning of being a standard to compare results to. Typically, controls are used to extend completeness in an experiment by isolating variables and drawing conclusions about such variables. In some embodiments, a control is a reaction or assay that is performed simultaneously with a test reaction or assay to provide a comparison. In one experiment, the "test" (i.e., the variable being tested) is applied. In a second experiment, the "control," the variable being tested, is not applied. In some embodiments, a control is a historical control (i.e., a test or assay previously performed, or a previously known amount or result). In some embodiments, a control is or includes a printed or saved record. A control can be a positive or negative control. In some embodiments, a control can be a "reference control," which is a sample used for comparison with a test sample to look for differences or for characterization purposes.
[0028] Gene Therapy: As used herein, the term "gene therapy" refers to any therapy that involves the direct or indirect administration of a nucleic acid to a subject. In certain instances, a protein having therapeutic value is expressed from the administered nucleic acid.
[0029] Identity: As used herein, the term "identity" refers to the overall relatedness between polymers, for example, between nucleic acid molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. For example, the calculation of the percentage identity of two nucleic acid sequences can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced into one or both of the first and second nucleic acid sequences for optimal alignment, and non-identical sequences can be ignored for comparison purposes). In certain embodiments, the length of the aligned sequence for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. The nucleotides at the corresponding nucleotide positions are then compared. If a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, the molecules are identical at this position. Taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of two sequences, the percentage of identity between two sequences is a function of the number of identical positions shared by the sequences. Comparison of sequences and determination of the percentage of identity between two sequences can be accomplished using mathematical algorithms. For example, the percentage of identity between two nucleotide sequences can be determined using the Mayers and Miller algorithm (CABIOS, 1989, 4: 11-17), which is incorporated into the ALIGN program (version 2.0), using a PAM120 residue weighting table, a gap length penalty of 12, and a gap penalty of 4. Alternatively, the percentage of identity between two nucleotide sequences can be determined using the GAP program of the GCG software package, using the NWSgapdna.CMP matrix. A variety of other sequence alignment programs are available and can be used to determine sequence identity, such as, for example, Clustal.
[0030] Improve, increase, or reduce: As used herein, the terms "improvement," "increase," or "reduce," or grammatical equivalents, refer to a value relative to a baseline measurement, e.g., a measurement in the same individual prior to the initiation of a treatment described herein, or a measurement in a control individual (or control individuals) in the absence of a treatment described herein. A "control individual" is an individual suffering from the same type and approximately the same severity of, e.g., Alzheimer's disease, as the individual being treated, and approximately the same age as the individual being treated (to ensure that the stage of the disease in the treated and control individual(s) is comparable).
[0031] Neurodegeneration: As used herein, the term "neurodegeneration" refers to the process in which one or more nerve cells are damaged, lose function, become dysfunctional, and / or die.Neurodegeneration encompasses both rapid and gradual types and intermediate types.Thus, neurodegenerative diseases, conditions, or symptoms are characterized in that the disease is typically associated with nerve cell damage and / or death.
[0032] subject: As used herein, the term "subject" refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate). Human includes prenatal and postnatal forms. In many embodiments, the subject is a human. A subject may be a patient, and refers to a human who visits a medical institution for diagnosis or treatment of a disease. The term "subject" is used interchangeably herein with "individual" or "patient." A subject may suffer from or be susceptible to a disease or disorder, but may or may not exhibit symptoms of the disease or disorder.
[0033] Suffering from: An individual "suffering from" a disease, disorder, and / or condition (e.g., Alzheimer's disease) has been diagnosed with or exhibits one or more symptoms of the disease, disorder, and / or condition.
[0034] Susceptible to: An individual who is "susceptible to" a disease, disorder, and / or condition may not have been diagnosed with and / or exhibit symptoms of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition (e.g., Alzheimer's disease) may be characterized by one or more of: (1) a genetic mutation associated with the onset of the disease, disorder, and / or condition; (2) a genetic polymorphism associated with the onset of the disease, disorder, and / or condition; (3) an increased and / or decreased expression and / or activity of a protein associated with the onset of the disease, disorder, and / or condition; (4) a habit and / or lifestyle associated with the onset of the disease, disorder, and / or condition; (5) a family history of the disease, disorder, and / or condition; (6) a response to a particular bacterium or virus; (7) exposure to a particular chemical. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition develops the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition does not develop the disease, disorder, and / or condition.
[0035] Therapeutically Effective Amount: As used herein, the term "therapeutically effective amount" refers to an amount of a therapeutic protein that confers a therapeutic effect on a treated subject at a reasonable benefit / risk ratio applicable to any medical treatment. The therapeutic effect can be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject shows signs of or feels the effect). In particular, "therapeutically effective amount" refers to an amount of a therapeutic protein or composition that is effective to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or prophylactic effect, for example, by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and / or similarly reducing the severity or frequency of symptoms of the disease. Therapeutically effective amounts are generally administered by a dosing regimen that may include multiple unit doses. For any particular therapeutic protein, the therapeutically effective amount (and / or the appropriate unit dose in an effective dosing regimen) may vary, for example, depending on the route of administration, combination with other pharmaceutical agents. In addition, the particular therapeutically effective amount (and / or unit dose) for any particular patient may depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the particular pharmaceutical agent being employed; the particular composition being employed; the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration, and / or excretion rate or metabolic rate of the particular fusion protein being employed; the duration of treatment; and similar factors as are well known in the medical arts.
[0036] Treatment: As used herein, the term "treatment" (also "treat" or "treating"), in its broadest sense, refers to any administration of a substance (e.g., a provided composition) that partially or completely relieves, ameliorates, relieves, inhibits, delays the onset of, reduces the severity of, and / or reduces the incidence of one or more symptoms, characteristics, and / or causes of a particular disease, disorder, and / or condition. In some embodiments, such treatment may be administered to subjects who do not exhibit symptoms of the relevant disease, disorder, and / or condition and / or subjects who exhibit only early signs of the disease, disorder, and / or condition. Alternatively, or in addition, in some embodiments, treatment may be administered to subjects who exhibit one or more established signs of the relevant disease, disorder, and / or condition. In some embodiments, treatment may be treatment to subjects who have been diagnosed as suffering from the relevant disease, disorder, and / or condition. In some embodiments, the treatment may be to a subject known to have one or more susceptibility factors that statistically correlate with an increased risk of developing the relevant disease, disorder, and / or condition.
[0037] Generally speaking, "PS1" refers to the presenilin 1 protein and "PS2" refers to the presenilin 2 protein, although in some instances, PS1 or PS2 are used to refer to the mRNA or the gene.
[0038] Detailed Description The present disclosure particularly provides compositions and methods for treating subjects with Alzheimer's disease and other neurodegenerative diseases, disorders and conditions based on the delivery of functional presenilin 1 (PS1) and / or presenilin 2 (PS2).In particular, the present disclosure contemplates gene therapy by providing a polynucleotide encoding presenilin 1 (PSEN1) and / or presenilin 2 (PSEN2) genes to a subject in need of treatment.However, in some embodiments, presenilin 1 (PS1) and / or presenilin 2 (PS2) proteins can also be used.
[0039] Various aspects of the present invention are described in detail in the following clauses. The use of these clauses is not meant to limit the present invention. Each clause may apply to any aspect of the present invention. In this application, the use of "or" means "and / or" unless otherwise stated.
[0040] Treatment methods As a non-limiting example, the method of the present invention includes gene therapy to express wild-type human presenilin 1 or presenilin 2 in subjects suffering from or susceptible to neurodegenerative diseases, such as Alzheimer's disease, associated with mutations (e.g., dominant-negative mutations) in PSEN1 or PSEN2. The purpose of such gene therapy is to promote the expression of PS1 or PS2, particularly in the brain of familial or sporadic AD patients, to correct or overcome defects in PS1 or PS2 expression and / or activity. In FAD patients, the gene therapy methods described herein are expected to result in increased expression of wild-type PS1 or PS2 in the brain, restoring the dysfunction of gamma-secretase activity associated with mutations in PS1 or PS2.
[0041] Mutations in the presenilin genes, PSEN1 and PSEN2, are highly penetrant and account for approximately 90% of all identified mutations in familial AD (FAD), highlighting their importance in AD pathogenesis. Over 260 separate mutations in PSEN1 have been reported, which are dominantly inherited and mostly missense mutations. Pathogenic PSEN1 mutations act in cis to impair mutant PS1 function and in trans to inhibit wild-type presenilin 1 (PS1) function (Heilig et al. J Neurosci 33:11606-717 (2013); Zhou et al. Proc Natl Acad Sci USA 114:12731-12736 (2017)). Typically, by their very nature, dominant-negative mutations cannot be restored by expression of the wild-type protein (Herskowitz, I. Nature, 329:219-222 (1987)). However, as shown herein, transfection of hPSEN1 cDNA into immortalized MEFs carrying heterologous or homozygous PSEN1 mutations restores the impaired gamma-secretase activity in such cells (see Examples below), indicating that surprisingly, high expression of wild-type PS1 protein can overcome the dominant-negative effect of mutant presenilin protein. Presenilins are catalytic subunits of the gamma-secretase complex, and also include nicastrin, APH-1 (anterior pharyngeal defect 1) and PEN2 (presenilin enhancer 2), all of which are required for the assembly, stability and activity of the gamma-secretase complex. Surprisingly, without wishing to be bound by theory, it is believed that wild-type presenilin protein may be able to replace mutant presenilin protein in the gamma-secretase complex based on the data of the present invention. Thus, expression of wild-type PS1 or PS2 protein can be used to restore the dysfunction of gamma-secretase expression and / or activity in AD patients.
[0042] The methods and compositions described herein can similarly be used to treat other neurodegenerative diseases, disorders or conditions.
[0043] Alzheimer's Disease The methods described herein may be used to treat or reduce the risk of developing subjects having all types of Alzheimer's disease, including, but not limited to, familial and sporadic Alzheimer's, early-onset or late-onset Alzheimer's disease. In some embodiments, the methods of the invention may be used to treat or reduce the risk of developing early-onset familial Alzheimer's disease (AD), which is associated with mutations in presenilin 1 (PS1) and / or presenilin 2 (PS2) (Sherrington, et al., Nature 375:754-760 (1995); Rogaev, et al., Nature 376:775-778 (1995); Levy-Lahad, et al., Science 269:970-973 (1995); Hiltunen, et al., Eur. J. Hum. Genet. 8:259-266 (2000); Jonghe, et al., Hum. Mol. Genet. 8:1529-1540 (1999); Tysoe, et al., Am. J. Hum. Genet. 62:70-76 (1998); Crook, et al., Nat. Med. 4:452-455 (1998), all of which are incorporated herein by reference.
[0044] In some embodiments, the methods of the invention may be used to treat subjects who have a mutation in a PSEN1 or PSEN2 allele, eg, a mutation that has a dominant-negative effect on the wild-type PS1 / PS2 protein. Exemplary mutations include C410Y, Δex9, G548, D257A, L166P, R278I, L435F, G384A, Y115H, and L392V, as well as N141I, G206A, H163R, A79V, S290C, A260P, A426P, A431E, R269H, L271V, C1410Y, E280G, P264L, E185D, L235V, and M146V mutations (see, e.g., Heilig et al., J. Neurosci., 33(28):11606-11617 (2013); Watanabe et al., J. Neurosci. 32(15):5085-5096 (2012); Brouwers et al., J. Neurosci., 32(15):5085-5096 (2012); al., 2008 Ann Med 40 (8): 562-83);Watanabe and Shen, PNAS November 28, 2017 114 (48) 12635-12637;Zhou et al., PNAS November 28, 2017 114 (48) 12731-12736;Hsu et al., Alzheimers Res Ther. 2018 Jul 18;10(1):67). Further exemplary mutations that may have a dominant-negative effect on wild-type PS protein include, in PSEN1: N32N; R35Q; D40del(delGAC); D40del(delACG); E69D; A79V; V82L; I83_M84del(DelIM, ΔI83 / M84, ΔI83 / ΔM84); I83T; M84V; L85P; P88L; V89L(G>T); V89L(G>C). ;C92S;V94M;V96F;V97L;T99A;F105C;F105I;F105L;F105V;R108Q;L113_I114insT(Intron4, InsTAC, p.113+1de lG, splice5);L113P;L113Q;Y115C;Y115D;Y115H;T116I;T116N;T116R;P117A;P117L;P117R;P117S;E120D(A>C);E120D(A>T);E120G;E120K;E123K;Q127_R128del(CAGA);InsG(G)(c.379_382delXXXXinsG);H131R;S132A;L134R;N135D;N135S;N135Y;A136G;M139I(G>C);M139I(G>A);M139K;M139L;M139T;M139V;V142F;I143F;I143M;I143N;I143T;I143V;M146I(G>C);M146I(G>T);M146I(G>A);M146L(A>C);M146L(A>T);M146V;T147I;T147P;L150P;L153V;Y154C;Y154N;Y156F;Y156_R157insIY;R157S;H163P;H163R;H163Y;A164V;W165C(G>C);W165C(G>T);W165G;L166H;L166P;L166R;L166V;L166del;I167del(TTAdel);I167del(TATdel);I168T;S169del(ΔS169、Ser169del、ΔS170);S169L;S169P;S170F;S170P;L171P;L173F(G>C);L173F(G>T);L173W;L174del;L174M;L174R;F175S;F176L;F177L;F177S;S178P;G183V;E184D;E184G;V191A;I202F;G206A;G206D;G206S;G206V;G209A;G209E;G209R;G209V;S212Y;I213F;I213L;I213T;H214D;H214N;H214Y;G217D;G217R;L219F;L219P;L219R;R220P;Q222H;Q222P;Q222R;Q223R;L226F;L226R;I229F;S230I;S230N;S230R;A231P;A231T;A231V;L232P;M233I(G>A);M233I(G>C);M233L(A>T);M233L(A>C);M233T;M233V;L235P;L235R;L235V;F237I;F237L;I238M;K239N;T245P;A246E;A246P;L248P;L248R;L250F;L250S;L250V;Y256S;A260V;V261F;V261L;L262F;L262V;C263F;C263R;P264L;G266S;P267A;P267L;P267S;R269G;R269H;L271V;V272A;E273A;E27 3G;T274R;A275V;R278I;R278K;R278S;R278T;E280A;(Paisa);E280G;E280K;L282F;L282R;L282V;F283 L;P284L;P284S;A285V;L286P;L286V;T291A;T291P;K311R;E318G;D333G;R352C;R352_S353insR;T354I ;R358Q;S365A;S365Y;R377M;R377W;G378E;G378V;G378fs;L381F;L381V;G384A;F386I;F386S;F388L;S3 90I;S390N;V391F;V391G;L392P;L392V;G394V;A396T;N405S;I408T;A409T;C410Y;V412I;I416T;G417S ;L418F;L420R;L424F;L424H;L424R;L424V;A426P;A431E;(Jalisco);A431V;A434C;A434T;L435F;P436 Q;P436S;I437V;I439S;I439V;T440del;869-2A>G;869-22_869-23ins18(ΔE9, Δ9, deltaE9);I238_K239 insI;S290C;T291_S319del(ΔE9Finn, Δ9Finn, Δ9);S290C;T291_S319del(ΔE9, Δ9);S290C;T291_S319del A>G(ΔE9, Δ9);S290C;T291_S319del G>A(ΔE9, Δ9);S290C;T291_S319del G>T(ΔE9, Δ9); or S290W;S291_R377del(Δ9-10, Delta9-10, p.Ser290_Arg377delinsTrp, g.73671948_73682054del) (mutations are named against Uniprot P49768.1 / GenBank reference number NM_000021.4), and in PSEN-2:T18M;R29H;G34S;R62C;R62H;P69A;R71W;K82R;A85V;V101M;K115Efs*;T122P;T122R;P123L;E126fs;E126K;S130L;V139M;N141I (Volga German);N141Y;L143H;V148I;K161R;R163H;H169N;M174V;S175C;G212V;V214L;Q228L;Y231C;I235F;A237V;L238F;L238P;M239I;M239V;A252T;A258T;T301M;K306fs;P334A;P334R;P348L;A377V;V393M;T430M; or D439A (mutations were identified using Uniprot P49810.1 / GenBank reference number NP_000438.2) mutations. See, e.g., Sun et al., Proc Natl Acad Sci USA. 2017;114:E476-E485;Heilig et al., J Neurosci. 2013 Jul 10;33(28):11606-17;Zhou et al., PNAS November 28, 2017 114 (48) 12731-12736. In some embodiments, the method may include determining that the subject has such a mutation, e.g., using methods known in the art;
[0045] Typically, amnesia or mild confusion is an early symptom of Alzheimer's disease. Gradually, cognitive impairment associated with Alzheimer's disease leads to memory loss, especially recent memory, disorientation and misunderstanding of spatial relationships; difficulties with language, writing, thinking and reasoning; changes in personality and behavior resulting in depression, anxiety, social withdrawal, mood swings, distrust of others, irritability and aggression; changes in sleep habits, wandering, loss of inhibitions, delusions, and ultimately death.
[0046] Other neurodegenerative diseases, disorders or conditions In addition to Alzheimer's disease, the methods of the invention may be used to treat other neurodegenerative diseases, disorders or conditions, including frontotemporal dementia, various types of memory loss, cognitive impairment including but not limited to mild cognitive impairment (MCI), or other conditions associated with loss of PS1, e.g., due to mutations that generate dominant-negative isoforms.
[0047] Presenilin 1 (PSEN1) and / or Presenilin 2 (PSEN2) Polynucleotides encoding presenilin 1 (PS1) or presenilin 2 (PS2) suitable for use in the compositions and methods described herein may comprise a full-length gene or a portion or fragment thereof encoding a protein that retains substantial gamma secretase activity of the wild-type protein, e.g., at least 50% of the gamma secretase activity, or at least 60, 70, 80, 90, or 95% of the activity of the wild-type protein, as determined by an in vitro gamma secretase assay, including, for example, the assay described in the Examples section (see also Watanabe et al., J. Neurosci. 32(15):5085-5096 (2012)). In some embodiments, suitable PS1 or PS2-encoding polynucleotides have sequences that are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the full-length wild-type genomic or cDNA PSEN1 or PSEN2 sequence, respectively. In some embodiments, suitable PSEN1 or PSEN2 genes encode protein sequences that are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the full-length wild-type PS1 or PS2 protein sequence, respectively. Exemplary wild-type genomic, cDNA, and protein sequences of human PSEN1 / PS1 or PSEN2 / PS2 are shown in Table 1 and below. Sequences for use in other species are known in the art. PS1 and PS2 are usually truncated into active N- and C-terminal fragments. PS1 is processed to produce two fragments, an N-terminal fragment of 28 kDa and a C-terminal fragment of 18 kDa, with the major intracellular proteolytic cleavage occurring at and near Met298 proximal to the large hydrophilic loop (Podlisny et al., Neurobiol Dis. 1997;3(4):325-37; Marambaud et al., EMBO J. 2002 Apr 15;21(8):1948-56).In addition, sequences comprising or encoding such truncated forms, for example sequences encoding amino acids 1-291, 1-292, 1-293, 1-294, 1-295, 1-296, 1-297, 1-298 or 1-299 of SEQ ID NO:5, or corresponding fragments of SEQ ID NOs:6-8, can be used in the methods and compositions described herein.
[0048] [Table 1]
[0049] >NM_000021.3 Human (Homo sapiens) presenilin 1 (PSEN1), transcript variant 1, mRNA (SEQ ID NO:1)
[0050] [ka] JPEG0007587423000003.jpg232160JPEG0007587423000004.jpg177160
[0051] >NM_007318.2 Human (Homo sapiens) presenilin 1 (PSEN1), transcript variant 2, mRNA (SEQ ID NO:2)
[0052] [ka] JPEG0007587423000006.jpg232160JPEG0007587423000007.jpg232160JPEG0007587423000008.jpg52160
[0053] >NM_000447.2 Human (Homo sapiens) presenilin 2 (PSEN2), transcript variant 1, mRNA (SEQ ID NO:3)
[0054] [ka]
[0055] >NM_012486.2 Human (Homo sapiens) presenilin 2 (PSEN2), transcript variant 2, mRNA (SEQ ID NO: 4)
[0056] [ka]
[0057] >NP_000012.1 Presenilin 1 isoform I-467 [Homo sapiens] (SEQ ID NO: 5)
[0058] [ka]
[0059] >NP_015557.2 Presenilin 1 isoform I-463 [Homo sapiens] (SEQ ID NO: 6)
[0060] [ka]
[0061] >NP_000438.2 Presenilin 2 isoform 1 [Homo sapiens] (SEQ ID NO: 7)
[0062] [ka]
[0063] >NP_036618.2 Presenilin 2 isoform 2 [Homo sapiens] (SEQ ID NO: 8)
[0064] [ka]
[0065] To determine the percentage of identity between two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison (e.g., for optimal alignment, gaps can be introduced into one or both of the first and second amino acid or nucleic acid sequences, and non-homologous sequences can be ignored for comparison). The length of the reference sequence that is aligned for comparison purposes is at least 80% of the length of the reference sequence, and in some embodiments, at least 90% or 100% of the length. The amino acid residues or nucleotides at the corresponding amino acid positions or nucleotide positions are then compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at this position. Considering the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences, the percentage of identity between the two sequences is a function of the number of identical positions shared by the sequences. In another embodiment, the percentage of identity of two amino acid sequences can be evaluated as a function of conservation of amino acid residues within the same amino acid family (e.g., positively charged, negatively charged, polar and uncharged, hydrophobicity) at corresponding positions in both amino acid sequences (e.g., the presence of an alanine residue in place of a valine residue at a particular position in both sequences indicates a high level of conservation, while the presence of an arginine residue in place of an aspartic acid residue at a particular position in both sequences indicates a low level of conservation).
[0066] For example, the percent identity of two amino acid sequences can be determined using the algorithm of Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453), which is incorporated into the GAP program in the GCG software package, using a Blossom scoring matrix, e.g., using the default for gap penalties, a gap extension penalty of 4, and a frameshift gap penalty.
[0067] Mutant presenilin 1 In some embodiments, the PS1 protein comprises a mutation. In some embodiments, the mutation is a conservative substitution. Such mutations include substitutions of any of isoleucine (I), valine (V), and leucine (L) with any other of these hydrophobic amino acids, substitutions of aspartic acid (D) with glutamic acid (E) and vice versa, substitutions of glutamine (Q) with asparagine (N) and vice versa, and substitutions of serine (S) with threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of a particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can often be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can often be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are often interchangeable in positions where the charge is a prominent feature of the amino acid residue and the different pKs of these two amino acid residues are not prominent. Still other mutations can be considered "conservative" in certain circumstances (see, for example, Table III of US20110201052; pages 13-15 "Biochemistry" 2nd ED. Stryer ed (Stanford University); Henikoff et al., PNAS 1992 Vol 89 10915-10919; Lei et al., J Biol Chem 1995 May 19; 270(20):11882-6).
[0068] In some embodiments, the method includes introducing one or more additional mutations into the human PS1 sequence (SEQ ID NO: 5 or 6). Thus, in some embodiments, the sequence may be at least 80%, 85%, 90%, 95% or 99% identical to a nucleotide sequence that is at least 60%, 70%, 80%, 90% or 100% identical to human PS1. In some embodiments, the method includes introducing one or more additional mutations into the human PS2 sequence (SEQ ID NO: 7 or 8). Thus, in some embodiments, the sequence may be at least 80%, 85%, 90%, 95% or 99% identical to a nucleotide sequence that is at least 60%, 70%, 80%, 90% or 100% identical to human PS2.
[0069] To determine the percentage of identity between two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced into one or both of the first and second amino acid or nucleic acid sequences for optimal alignment, and non-homologous sequences can be ignored for comparison purposes). The length of the reference sequence aligned for comparison purposes is typically at least 80% of the length of the reference sequence, and in some embodiments, at least 90% or 100% of the length. The amino acid residues or nucleotides at the corresponding amino acid or nucleotide positions are then compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at this position (as used herein, amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). Considering the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences, the percentage of identity between the two sequences is a function of the number of identical positions shared by the sequences. In another embodiment, the percentage of identity of two amino acid sequences can be evaluated as a function of conservation of amino acid residues within the same amino acid family (e.g., positively charged, negatively charged, polar and uncharged, hydrophobicity) at corresponding positions in both amino acid sequences (e.g., the presence of an alanine residue in place of a valine residue at a particular position in both sequences indicates a high level of conservation, while the presence of an arginine residue in place of an aspartic acid residue at a particular position in both sequences indicates a low level of conservation).
[0070] For purposes of the methods of the present invention, comparison of sequences and determination of percent identity between two sequences can be accomplished using a Blossom 62 scoring matrix, with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.
[0071] Delivery Vector The nucleic acid encoding PS1 or PS2 polypeptide or its therapeutically active fragment can be incorporated into a genetic construct and used as part of a gene therapy protocol. For example, the targeting of an expression vector for in vivo delivery and expression of a polynucleotide encoding PS1 or PS2 polypeptide or its active fragment in a specific cell type, particularly in cerebral cortical neuronal cells, is described herein. Such expression constructs of components can be administered by any effective carrier, for example, any formulation or composition that can effectively deliver the genetic component to cells in vivo. The method includes inserting the gene into a viral vector, preferably an adeno-associated virus. The viral vector typically transduces cells directly.
[0072] Viral vectors capable of highly efficient transduction of CNS neurons are available, including rAAV (e.g., AAV1-AAV12) vectors of any serotype, recombinant or chimeric AAV vectors, as well as lentivirus or other suitable viral vectors. In some embodiments, polynucleotides encoding PS1 or PS2 are operably linked to a promoter suitable for expression in the CNS. For example, neuronal subtype-specific promoters, such as the alpha-calcium / calmodulin kinase 2A promoter, may be used to target excitatory neurons. Alternatively, pan-neuronal promoters, such as the synapsin I promoter, may be used to drive PS1 or PS2 expression. Other exemplary promoters include, but are not limited to, cytomegalovirus (CMV) early enhancer / promoter; hybrid CMV enhancer / chicken β-actin (CBA) promoter; promoter that includes CMV early enhancer element, chicken β-actin gene first exon and first intron, and rabbit β-globulin gene splice acceptor (commonly referred to as "CAG promoter"); or 1.6 kb hybrid promoter consisting of CMV immediate early enhancer and CBA intron 1 / exon 1 (commonly referred to as CAGGS promoter; Niwa et al. Gene, 108:193-199 (1991)). CAGGS promoter (Niwa et al., 1991) has been found to be ubiquitous and long-term expressed in the brain (Klein et al., Exp. Neurol. 176:66-74 (2002)). The typical method for in vivo introduction of nucleic acid into cells is by using viral vectors that contain nucleic acid, for example, cDNA that codes for PS1 or PS2.In particular, the infection of cells with viral vectors has the advantage that the majority of targeted cells can receive nucleic acid.In addition, the molecules encoded in the viral vector, for example, by the cDNA contained in the viral vector, are efficiently expressed in cells that receive viral vector nucleic acid.
[0073] A particularly useful viral vector system for the delivery of nucleic acid is the adeno-associated virus (AAV). The adeno-associated virus is a naturally occurring defective virus that requires another virus, such as adenovirus or herpesvirus, as a helper virus for efficient replication and productive life cycle (for review, see Muzyczka et al., Curr. Topics in Micro and Immunol.158:97-129 (1992)). AAV vectors can efficiently transduce a variety of cell types and cause long-term expression of transgenes in vivo. AAV vector genomes can persist in cells as episomes, but vector integration has been observed (see, e.g., Deyle and Russell, Curr Opin Mol Ther. 2009 Aug; 11(4): 442-447; Asokan et al., Mol Ther. 2012 Apr; 20(4): 699-708; Flotte et al., Am. J. Respir. Cell. Mol. Biol. 7:349-356 (1992); Samulski et al., J. Virol. 63:3822-3828 (1989); and McLaughlin et al., J. Virol. 62:1963-1973 (1989)). AAV vectors, such as AAV2, have been used extensively for gene augmentation or replacement and have shown therapeutic efficacy in a wide range of animal models as well as in the clinic. See, e.g., Mingozzi and High, Nature Reviews Genetics 12, 341-355 (2011); Deyle and Russell, Curr Opin Mol Ther. 2009 Aug; 11(4): 442-447; Asokan et al., Mol Ther. 2012 Apr; 20(4): 699-708. AAV vectors containing as little as 300 base pairs of AAV can be packaged and can result in recombinant protein expression.Protocols for generating recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses are known in the art and can be found, for example, in Ausubel, et al., eds., Current Protocols in Molecular Biology, Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard manuals.The use of AAV vectors to deliver constructs for expression in the brain is described, for example, in Iwata et al., Sci Rep. 2013;3:1472;Hester et al., Curr Gene Ther. 2009 Oct;9(5):428-33;Doll et al., Gene Therapy 1996, 3(5):437-447;and Foley et al., J Control Release. 2014 Dec 28;196:71-8.
[0074] Therefore, in some embodiments, the nucleic acid encoding PS1 or PS2 is present in a vector for gene therapy, for example, an AAV vector.In some examples, the AAV vector is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO, AAV11 and AAV12.
[0075] The vector described herein can be a pseudotype vector.Pseudotyping provides a mechanism for regulating the target cell population of vector.For example, pseudotype AAV vector can be utilized in various methods described herein.Pseudotype vector is a vector that contains the genome of one vector, for example, the genome of one AAV serotype, in the capsid of a second vector, for example, the second AAV serotype.The method of pseudotyping is well known in the art. For example, vectors can be pseudotyped with envelope glycoproteins from the rhabdovirus vesicular stomatitis virus (VSV) serotypes (Indiana and Chandipura strains), rabies virus (e.g., various Evelyn-Rokitnicki-Abelseth ERA strains and challenge virus standard (CVS)), Lyssavirus Mokola virus, rabies-associated virus, vesicular stomatitis virus (VSV), Mokola virus (MV), lymphocytic choriomeningitis virus (LCMV), rabies virus glycoprotein (RV-G), glycoprotein type B (FuG-B), a mutant of FuG-B (FuG-B2), or Moloney murine leukemia virus (MuL V). The viruses may be pseudotyped for transduction of one or more neural cells or groups of cells.
[0076] Illustrative examples of pseudotype vectors include, but are not limited to, recombinant AAV2 / 1, AAV2 / 2, AAV2 / 5, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV9, AAVrhlO, AAV11 and AAV12 serotype vectors.It is known in the art that such vectors can be modified to include transgenes encoding human proteins or other proteins.In certain examples, the present disclosure can include pseudotype AAV9 or AAVrhlO viral vectors that include the nucleic acid disclosed herein.See Viral Vectors for Gene Therapy: Methods and Protocols, ed. Machida, Humana Press, 2003.
[0077] In some cases, a vector of a particular AAV serotype can be selected based on the intended use, for example, based on the intended route of administration.
[0078] Various methods for the application of AAV vector constructs in gene therapy are known in the art, including methods of modification, purification, and preparation for administration to human subjects (see, for example, Viral Vectors for Gene Therapy: Methods and Protocols, ed. Machida, Humana Press, 2003). In addition, AAV-based gene therapy targeting CNS cells has been described (see, for example, U.S. Patent Nos. 6,180,613 and 6,503,888). High titer AAV preparation can be performed using techniques known in the art, such as those described in, for example, U.S. Patent No. 5,658,776.
[0079] Vector construct refers to a polynucleotide molecule that contains all or part of a viral genome and a transgene.In some cases, gene transfer can be mediated by a DNA virus vector, such as adenovirus (Ad) or adeno-associated virus (AAV).Other vectors that are useful in gene therapy methods are known in the art.For example, the construct disclosed herein can include alphavirus, herpesvirus, retrovirus, lentivirus, or vaccinia virus.
[0080] Adenoviruses are a relatively well-characterized group of viruses, and include more than 50 serotypes (see, for example, International Publication No. WO 95 / 27071, which is incorporated herein by reference). Adenoviruses are more amenable to the application of molecular biology techniques, and may not require integration into the host cell genome. Recombinant Ad-derived vectors have been constructed, including vectors that reduce the possibility of recombination and generation of wild-type viruses (see, for example, International Patent Publication Nos. WO 95 / 00655 and WO 95 / 11984, which are incorporated herein by reference). Wild-type AAV has high infectivity and can integrate into the host genome with high specificity (see, for example, Hermonat and Muzyczka 1984 Proc. Natl. Acad. Sci., USA 81:6466-6470 and Lebkowski et al. 1988 Mol. Cell. Biol. 8:3988-3996).
[0081] Non-natural regulatory sequence, gene regulatory sequence, promoter, non-coding sequence, intron or coding sequence can be included in the nucleic acid disclosed herein.The inclusion of nucleic acid that codes for nucleic acid tag or signaling sequence or protein tag or protein signaling sequence is further discussed herein.Typically, coding region is operatively linked with one or more regulatory nucleic acid components.
[0082] The promoter contained in the nucleic acid disclosed herein can be a tissue or cell type specific promoter, a promoter specific to multiple tissues or cell types, an organ specific promoter, a promoter specific to multiple organs, a generalized or ubiquitous promoter, or a nearly generalized or ubiquitous promoter.Also, promoters with stochastic expression, inducible expression, conditional expression, or conversely, discontinuous, irregular, or unpredictable expression are included within the scope of this disclosure.Promoter can include any of the above characteristics or other promoter characteristics known in the art.
[0083] In a clinical setting, gene delivery systems for therapeutic genes can be introduced into a subject by any of several methods, each of which is known in the art. For example, pharmaceutical preparations of gene therapy systems can be introduced systemically, for example, by intravenous injection, and specific transduction of proteins in target cells occurs primarily due to the specificity of transfection provided by the gene delivery vehicle, cell type or tissue type expression, or a combination thereof, by transcriptional control sequences that regulate the expression of receptor genes. In other embodiments, the initial delivery of recombinant genes is more restricted, and introduction into a subject is highly localized. For example, gene delivery vehicles can be introduced by catheter (see U.S. Pat. No. 5,328,470) or, for example, optionally by stereotactic injection into the cisterna magna, ventricle, lumbar intrathecal cavity, or direct injection into the hippocampus (e.g., Chen et al., PNAS USA 91: 3054-3057 (1994)). In some embodiments, methods of delivery of the presenilin-expressing viruses include intravenous, intrathecal, intraventricular, intracisternal, and stereotactic intraparenchymal administration.
[0084] The method can be further optimized through preclinical trials to achieve the best recovery of neurodegeneration, dementia, synaptic dysfunction and molecular degeneration in presenilin conditional double knockout mice and presenilin 1 knock-in mice expressing FAD mutation.
[0085] The pharmaceutical preparation of the gene therapy construct can include the gene delivery system essentially in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is embedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells, thereby producing the gene delivery system.
[0086] Delivery Formulations and Pharmaceutical Compositions In some embodiments, the polynucleotides described herein for in vivo delivery to target tissues are encapsulated or associated with nanoparticles.Methods for packaging into nanoparticles are well known in the art and are described, for example, in Bose S, et al (Role of Nucleolin in Human Parainfluenza Virus Type 3 Infection of Human Lung Epithelial Cells. J. Virol. 78:8146. 2004);Dong Y et al. Poly(d,l-lactide-co-glycolide) / montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:6068. 2005);Lobenberg R. et al (Improved body distribution of 14C-labelled AZT bound to nanoparticles in rats determined by radioluminography. J Drug Target 5:171.1998);Sakuma SR et al (Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int J Pharm 177:161. 1999); Virovic L et al. Novel delivery methods for treatment of viral hepatitis: an update. Expert Opin Drug Deliv 2:707.2005); and Zimmermann E et al, Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm 52:203. 2001).In some embodiments, one or more polynucleotides are delivered to a target tissue in vivo by a vesicle, e.g., a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.). In some embodiments, lipid-based nanoparticles (LNPs) are used. See, e.g., Robinson et al., Mol Ther. 2018 Aug 1;26(8):2034-2046; U.S. Pat. No. 9,956,271.
[0087] The methods and compositions of the present invention include microvesicles or preparations thereof, which may include one or more therapeutic molecules, e.g., polynucleotides or RNA, as described herein. "Microvesicles" as the term is used herein refers to membrane-derived microvesicles, including a wide range of extracellular vesicles, including exosomes, microparticles, and excreted microvesicles secreted by many cell types under both normal physiological and pathological conditions. See, for example, EP 2010663. The methods and compositions described herein can be applied to microvesicles of any size, in one embodiment, 30-200 nm, in one embodiment, 30-800 nm, in one embodiment, up to 2 μm. The methods and compositions described herein can also be broadly applied to any extracellular vesicle, the term encompassing exosomes, excreted microvesicles, oncosomes, ectosomes, and retrovirus-like particles. Such microvesicles or preparations are generated by the methods described herein. As the term is used herein, a microvesicle preparation refers to a population of microvesicles obtained / prepared from the same cellular source. Such preparations are produced, for example, by culturing cells expressing the nucleic acid molecules of the present invention in vitro and isolating the microvesicles produced by the cells. Methods for isolating such microvesicles are known in the art (Thery et al., Isolation and characterization of exosomes from cell culture supernatants and biological fluids, in Current Protocols Cell Biology, Chapter 3, 322, (John Wiley, 2006); Palmisano et al., (Mol Cell Proteomics. 2012 August; 11(8):230-43) and Waldenstrom et al., ((2012) PLoS ONE 7(4): e34653.doi: 10.1371 / journal.pone.0034653)), some examples of which are described herein.Such techniques for isolating microvesicles from cells in culture include, but are not limited to, sucrose gradient purification / separation and differential centrifugation and may be adapted for use in the methods or compositions described herein. See, e.g., EP 2010663.
[0088] In some embodiments, the microvesicles are isolated by gently centrifuging the culture medium of the donor cells (e.g., about 300 g) for a period sufficient to separate the cells from the medium (e.g., about 15 min). This leaves the microvesicles in the supernatant, thus obtaining the microvesicle preparation. In one embodiment, the culture medium or supernatant from the gentle centrifugation is further strongly centrifuged (e.g., about 16,000 g) for a period sufficient to precipitate the cell debris (e.g., about 30 min). This leaves the microvesicles in the supernatant, thus obtaining the microvesicle preparation. In one embodiment, the culture medium, the gently centrifuged preparation, or the strongly centrifuged preparation is subjected to filtration (e.g., through a 0.22 μm filter or a 0.8 μm filter), thereby allowing the microvesicles to pass through the filter. In one embodiment, the filtrate is subjected to a final ultracentrifugation (e.g., about 110,000 g) for a period sufficient to precipitate the microvesicles (e.g., about 80 min). The resulting pellet contains the microvesicles and can be resuspended in a large volume of buffer to obtain a useful concentration for further use, thereby obtaining a microvesicle preparation. In one embodiment, the microvesicle preparation is generated by sucrose density gradient purification. In one embodiment, the microvesicles are further treated with DNAse (e.g., DNAse I) and / or RNAse and / or proteinase to remove any externally contaminating DNA, RNA, or protein, respectively. In one embodiment, the microvesicle preparation includes one or more RNAse inhibitors.
[0089] The molecules contained within the microvesicle preparation include therapeutic molecules. Typically, the microvesicles in the preparation are a heterogeneous population, with each microvesicle containing a complement of molecules that may or may not differ from those of other microvesicles in the preparation. The therapeutic molecule content in the microvesicle preparation can be expressed either quantitatively or qualitatively. One such method is to express the content as a percentage of the total molecules in the microvesicle preparation. By way of example, if the therapeutic molecule is an mRNA, the content can be expressed as a percentage of the total RNA content or as a percentage of the total mRNA content of the microvesicle preparation. Similarly, if the therapeutic molecule is a protein, the content can be expressed as a percentage of the total protein in the microvesicle. In one embodiment, the therapeutic microvesicles produced by the methods described herein or preparations thereof contain a detectable and statistically significant increased amount of the therapeutic molecule when compared to microvesicles obtained from control cells (cells obtained from the same source that have not been subjected to chemical manipulation to increase expression of the therapeutic molecule). In one embodiment, the therapeutic molecule is present in an amount at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% greater than in microvesicles obtained from control cells. Even higher levels of enrichment may be achieved. In one embodiment, the therapeutic molecule is present in the microvesicles or preparations thereof at least 2-fold greater than in control cell microvesicles. Even higher fold enrichments may be obtained (e.g., 3, 4, 5, 6, 7, 8, 9 or 10-fold).
[0090] In one embodiment, a relatively high percentage of the microvesicle content is a therapeutic molecule (e.g., achieved by high expression or specific targeting of the molecule to the microvesicle). In one embodiment, the microvesicle content of therapeutic molecules is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the total (homologous) molecule content (e.g., the therapeutic molecule is mRNA and is about 10% of the total mRNA content of the microvesicle). Even higher levels of enrichment may be achieved. In one embodiment, the therapeutic molecule is present in the microvesicle or preparation thereof at least 2-fold more than all other such (homologous) molecules. Even higher fold enrichments may be obtained (e.g., 3, 4, 5, 6, 7, 8, 9 or 10-fold). EXAMPLES
[0091] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
[0092] Example 1 Pyramidal neurons from patients with sporadic Alzheimer's disease (AD) show reduced levels of PSEN1 and PSEN2 mRNA Presenilin (PS) proteins are catalytic subunits of gamma-secretase, which is required for the generation of Aβ peptides. Mutations in the presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes are associated with 90% of cases of familial Alzheimer's disease (FAD). PSEN mutations associated with FAD and frontotemporal dementia cause loss of presenilin expression and function, resulting in reduced gamma-secretase activity (Xia et al., Neuron. 2015 Mar 4;85(5):967-81; Watanabe et al., J Neurosci. 2012 Apr 11;32(15):5085-96; Brouwers et al., 2008 Ann Med 40 (8): 562-83).
[0093] Individual pyramidal neurons were harvested using laser capture microdissection, and 300 neurons per human brain were pooled together for RNA preparation (PicoPure RNA Isolation Kit, Life Technologies, KIT0204). qRT-PCR was performed using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA polymerase (Life Technologies). The sequences of the primers used are listed in Table 2.
[0094] [Table 2]
[0095] PSEN1 and PSEN2 mRNA levels were reduced in laser-dissected pyramidal neurons from hippocampal CA1 pyramidal neurons of sporadic AD patients ( Fig. 1A-B ).
[0096] [Example 2] Dose-dependent reduction of gamma-secretase activity in MEFs carrying heterozygous and homozygous PSEN1 mutations method Generation of immortalized Psen mutant MEFs Mouse embryonic fibroblasts (MEFs) carrying various Psen1 genotypes were maintained in medium supplemented with 10% FBS and 1% penicillin and streptomycin. 300,000 MEFs were immortalized in 6-well plates by transfection with 1 μg of CMV-SV40. MEFs transfected with CMV-SV40 were compared with MEFs transfected with CMV-GFP (1 μg), which stopped dividing at approximately passage 7.
[0097] Transfection of NdE and hPS1 To determine whether γ-secretase activity was impaired in various immortalized Psen mutant MEFs, CMV-NotchΔE (5 ng) was transiently transfected into MEFs in 6-well plates using Lipofectamine LTX (ThermoFisher Scientific 15338030) according to the manufacturer's instructions.
[0098] Approximately 24 hours after transfection, cells were lysed in RIPA buffer: 50 mM TrisCl (pH 7.6), 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, protease inhibitor cocktail (Sigma), 1 mM DTT. Proteins (40 μg) were resolved on NuPAGE gels (Invitrogen) and transferred to nitrocellulose membranes. Primary antibodies were rabbit anti-cleaved Notch1 Val1744 (Cell Signaling), rabbit anti-PS1 NTF (Calbiochem) recognizing both mouse and human PS1, mouse anti-cMyc (Sigma) or rabbit anti-tubulin (Cell Signaling). Membranes were then incubated with dye-conjugated secondary antibodies (Licor goat anti-rabbit IRdye800, goat anti-mouse IRdye800 or goat anti-rabbit IRdye680). Signals were quantified using an Odyssey Infrared Imaging System (LI-COR Biosciences). γ-secretase activity, measured by NICD production, is reduced in L435F KI / + MEFs and further reduced in KI / KI and PS1− / − MEFs (Figure 3A).
[0099] [Example 3] Different PS genotypes: PS1 + / + , PS1 L435F / + , PS1 + / - , PS1 L435F / L435F , PS1 - / - and PS1 - / - ;PS2 - / - Dose-dependent restoration of γ-secretase activity in MEFs bearing To determine whether the reduced γ-secretase activity associated with PSEN1 mutations could be corrected by introduction of wild-type (WT) hPS1, we compared the different PS genotypes, PS1 + / + , PS1 L435F / + , PS1 + / - , PS1 L435F / L435F , PS1 - / - and PS1 - / - ;PS2 - / -We obtained primary MEFs from embryos carrying the .ALPHA.-deficient (DKO) mouse model. Immortalized MEFs were transiently transfected with CMV-NdelE and γ-secretase activity was assessed by measuring the levels of NICD and PS1 NTF / CTFs. NICD levels were reduced in a PS1 dose-sensitive manner and were undetectable in DKO cells (Figure 3A). NICD levels were reduced, but not PS1 NTF / CTFs. L435F / L435F MEF ("L435F KI / KI" MEF) and PS1 - / - Although de novo NICD generation was detectable in MEFs (Fig. 3A), de novo NICD generation was not observed in L435F KI / KI and PS1 - / - In vitro γ-secretase assays using embryonic brain were undetectable (Xia et al., Neuron. 2015 Mar 4;85(5):967-81). Without wishing to be bound by any particular theory, applicants believe that this is due to the low levels of PS2 normally expressed in embryonic brain compared to MEFs, and the low levels of PS2 in L435F KI / KI and PS1 - / - We hypothesized that this may be due to lower total PS activity in the brain compared to MEFs. To test this hypothesis, we L435F / + ;PS2 - / - γ-secretase activity was measured in MEFs, and PS1 L435F / + γ-secretase activity was significantly increased in PS1 cells compared with MEFs. L435F / + ;PS2 - / - In MEF, PS1 L435F / + was lower compared to MEFs (Fig. 3B).
[0100] To determine whether the impaired γ-secretase activity in various PS mutant MEFs could be restored by introduction of WT hPS1, different amounts (0, 20, 40, 80 ng) of wild-type hPS1 cDNA (pCI-hPS1) were transfected into MEFs together with CMV-NdelE. Notably, increasing amounts of pCI-hPS1 transfected into MEFs induced accumulation of PS1 protein, as well as the mutant (PS1 L435F / + , PS1 L435F / + ;PS2 - / -This resulted in restoration of PS1 NTF and NICD levels in (HK, DKO, and DKO) MEFs (Figure 3B), indicating that exogenous WT hPS1 can restore impaired γ-secretase activity in various PS mutant MEFs.
[0101] Other embodiments While the present invention has been described in conjunction with a detailed description of the invention, it will be understood that the foregoing description is intended to be illustrative and not limiting of the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. The present invention may provide the following aspects. [1] A method for treating a neurodegenerative disease, disorder or condition, comprising the step of administering a polynucleotide encoding presenilin 1 (PS1) and / or presenilin 2 (PS2) protein to a subject in need of treatment, wherein the subject has one or more mutations in at least one allele of PSEN1 and / or PSEN2 that encodes a dominant-negative PS1 or PS2 protein isoform. [2] The method according to [1] above, wherein the neurodegenerative disease, disorder or condition is Alzheimer's disease. [3] The method according to [2] above, wherein the Alzheimer's disease is familial Alzheimer's disease. [4] The method according to [3] above, wherein the subject has an E280A, Y115H, L166P, C410Y, Δex9, G548, D257A, R278I, L435F, G384A or L392V mutation in the PSEN1 gene, or an N141I, G206A, H163R, A79V, S290C, A260P, A426P, A431E, R269H, L271V, C1410Y, E280G, P264L, E185D, L235V or M146V mutation in the PSEN1 gene. [5] The method according to [3] above, wherein the Alzheimer's disease is sporadic Alzheimer's disease. [6] The method according to [3] above, wherein the Alzheimer's disease is late-onset or early-onset Alzheimer's disease. [7] The method according to [1] above, wherein the neurodegenerative disease, disorder or condition is frontotemporal dementia. [8] The method according to [1] above, wherein the neurodegenerative disease, disorder or condition is memory loss. [9] The method according to [1] above, wherein the neurodegenerative disease, disorder or condition is cognitive decline or cognitive impairment.
[10] The method according to [9] above, wherein the cognitive impairment is mild cognitive impairment (MCI).
[11] The method according to any one of the above-mentioned [1] to
[10] , comprising administering the polynucleotide in a vector, exosome, or lipid-based nanoparticle (LNP).
[12] The method according to
[11] above, wherein the vector is a viral vector.
[13] The method according to
[12] above, wherein the viral vector is an adeno-associated viral (AAV) vector.
[14] The method according to
[13] above, wherein the AAV vector is selected from AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh10, AAV11, AAV12, AAV2 / 1, AAV2 / 2, AAV2 / 5, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV2 / 9, AAV2 / rh10, AAV2 / AAV11 or AAV2 / AAV12.
[15] The method according to
[11] above, wherein the viral vector is a lentiviral vector.
[16] The method according to
[11] above, wherein the viral vector is a retroviral vector.
[17] The method according to any one of the above-mentioned [1] to
[16] , wherein the polynucleotide comprises a presenilin 1 (PSEN1) gene or mRNA.
[18] The method according to any one of the above-mentioned [1] to
[17] , wherein the polynucleotide comprises a presenilin 2 (PSEN2) gene or mRNA.
[19] The method according to any one of the above-mentioned [1] to
[18] , wherein the polynucleotide comprises a presenilin 1 (PSEN1) gene or mRNA, and a presenilin 2 (PSEN2) gene or mRNA.
[20] The method according to any of the above-mentioned [1] to
[19] , wherein the polynucleotide encoding PS1 comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:1 or SEQ ID NO:2.
[21] The method according to any of the above-mentioned [1] to
[20] , wherein the polynucleotide encoding PS2 comprises a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:3 or SEQ ID NO:4.
[22] The method according to any one of the above-mentioned [1] to
[21] , wherein the polynucleotide encoding presenilin 1 (PS1) and / or presenilin 2 (PS2) is operably linked to a promoter.
[23] The method according to
[22] above, wherein the promoter is a pan-neuronal promoter.
[24] The method according to
[23] above, wherein the pan-neuronal promoter is a synapsin I promoter.
[25] The method according to
[22] above, wherein the promoter is a neuronal subtype-specific promoter.
[26] The method according to
[25] above, wherein the neuronal subtype-specific promoter is an alpha-calcium / calmodulin kinase 2A promoter.
[27] The method according to any of the above-mentioned [1] to
[26] , wherein the polynucleotide encoding PS1 and / or PS2 is administered to the CNS of the subject in need of treatment.
[28] The method according to
[27] above, wherein the polynucleotides encoding PS1 and / or PS2 are administered to the CNS by intravenous delivery.
[29] The method according to
[27] above, wherein the polynucleotides encoding PS1 and / or PS2 are administered directly to the CNS by intrathecal delivery.
[30] The method according to
[27] above, wherein the polynucleotides encoding PS1 and / or PS2 are administered directly to the CNS by intracisternal delivery.
[31] The method according to
[27] above, wherein the polynucleotides encoding PS1 and / or PS2 are administered directly to the CNS by intraventricular delivery.
[32] The method according to
[27] above, wherein the polynucleotides encoding PS1 and / or PS2 are administered directly to the CNS by stereotactic injection into specific brain regions, optionally the cisterna magna, ventricles, lumbar intrathecal cavity, or direct injection into the hippocampus.
[33] A polynucleotide sequence encoding presenilin 1 (PS1) and / or presenilin 2 (PS2) protein for use in treating a neurodegenerative disease, disorder or condition in a subject, wherein the subject has one or more mutations in at least one allele of PSEN1 and / or PSEN2 that encode a dominant-negative PS1 or PS2 protein isoform.
[34] A vector comprising a polynucleotide sequence encoding presenilin 1 (PS1) and / or presenilin 2 (PS2) protein for use in treating a subject with a neurodegenerative disease, disorder or condition, wherein the sequence encoding PS1 and / or PS2 is operably linked to a promoter causing expression of said PS1 and / or PS2 in the brain, wherein the subject has one or more mutations in at least one allele of PSEN1 and / or PSEN2 that encode a dominant-negative PS1 or PS2 protein isoform.
[35] A vector for use as described in
[34] above, which is a viral vector.
[36] The vector for use according to
[35] above, wherein the viral vector is an adeno-associated viral (AAV) vector.
[37] The vector for use according to
[36] above, wherein the AAV vector is selected from AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh10, AAV11, AAV12, AAV2 / 1, AAV2 / 2, AAV2 / 5, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV2 / 9, AAV2 / rh10, AAV2 / AAV11 or AAV2 / AAV12, preferably AAV9 or AAVrh10.
[38] The vector for use according to
[35] above, wherein the viral vector is a lentiviral vector.
[39] The vector for use according to
[35] above, wherein the viral vector is a retroviral vector.
[40] The vector for use according to
[34] above, wherein the promoter is a pan-neuronal promoter.
[41] The vector for use according to
[40] above, wherein the pan-neuronal promoter is the synapsin I promoter.
[42] The vector for use according to
[34] above, wherein the promoter is a neuronal subtype-specific promoter.
[43] The vector for use according to
[42] above, wherein the neuronal subtype-specific promoter is the alpha-calcium / calmodulin kinase 2A promoter.
[44] A polynucleotide for use according to
[33] above, or a vector for use according to any of
[34] to
[43] above, wherein the sequence encoding PS1 comprises a nucleotide sequence that is at least 80%, 85%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:1 or SEQ ID NO:2.
[45] A polynucleotide for use as described in
[33] above, or a vector for use as described in any of
[34] to
[43] above, wherein the sequence encoding PS2 comprises a nucleotide sequence that is at least 80%, 85%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 3 or SEQ ID NO: 4.
[46] The polynucleotide for use according to
[33] above, or the vector for use according to any of
[34] to
[45] above, wherein the neurodegenerative disease, disorder or condition is Alzheimer's disease.
[47] The polynucleotide or vector for use according to
[46] above, wherein the Alzheimer's disease is familial Alzheimer's disease.
[48] The polynucleotide or vector for use according to
[46] above, wherein the Alzheimer's disease is sporadic Alzheimer's disease.
[49] The polynucleotide or vector for use according to
[46] above, wherein the Alzheimer's disease is late-onset or early-onset Alzheimer's disease.
[50] The polynucleotide for use according to
[33] above, or the vector for use according to any of
[34] to
[45] above, wherein the neurodegenerative disease, disorder or condition is frontotemporal dementia.
[51] The polynucleotide for use according to
[33] above, or the vector for use according to any one of
[34] to
[45] above, wherein the neurodegenerative disease, disorder or condition is memory loss.
[52] The polynucleotide for use according to
[33] above, or the vector for use according to any of
[34] to
[45] above, wherein the neurodegenerative disease, disorder or condition is cognitive decline or cognitive impairment.
[53] The polynucleotide for use according to
[33] above, or the vector for use according to any one of
[34] to
[45] above, wherein the cognitive impairment is mild cognitive impairment (MCI).
[54] A polynucleotide for use as defined in any one of
[33] or
[44] to
[53] above, which is combined with or formulated for delivery by an exosome, or a lipid-based nanoparticle (LNP).
Claims
1. A pharmaceutical composition for use in the treatment of Alzheimer's disease, comprising: The pharmaceutical composition comprises: i) a polypeptide encoding the wild-type presenilin 1 (PS1) protein and comprising the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6, and / or ii) a polypeptide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6 and encoding a protein having gamma-secretase activity. Including, the subject has one or more mutations selected from the group consisting of E280A, Y115H, L166P, C410Y, Δex9, G548, D257A, R278I, L435F, G384A and L392V mutations in the PSEN1 gene, and N141I, G206A, H163R, A79V, S290C, A260P, A426P, A431E, R269H, L271V, C410Y, E280G, P264L, E185D and L235V mutations in the PSEN1 gene; The pharmaceutical composition.
2. A pharmaceutical composition for use in the treatment of Alzheimer's disease, comprising: The pharmaceutical composition comprises: i) a polynucleotide sequence encoding the wild-type presenilin 1 (PS1) protein and comprising the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and / or ii) a polynucleotide sequence that comprises a nucleotide sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:2 and encodes a protein that has gamma-secretase activity. A vector comprising said polynucleotide sequence is operably linked to a promoter causing expression of said PS1 protein and / or said protein having gamma-secretase activity in the brain; the subject has one or more mutations selected from the group consisting of E280A, Y115H, L166P, C410Y, Δex9, G548, D257A, R278I, L435F, G384A and L392V mutations in the PSEN1 gene, and N141I, G206A, H163R, A79V, S290C, A260P, A426P, A431E, R269H, L271V, C410Y, E280G, P264L, E185D and L235V mutations in the PSEN1 gene; The pharmaceutical composition.
3. The pharmaceutical composition of claim 2 , wherein the vector is a viral vector.
4. 4. The pharmaceutical composition of claim 3, wherein the viral vector is an adeno-associated viral (AAV) vector, preferably the AAV vector is selected from AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrhlO, AAV11, AAV12, AAV2 / 1, AAV2 / 2, AAV2 / 5, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV2 / 9, AAV2 / rhlO, AAV2 / AAV11 or AAV2 / AAV12, preferably AAV9 or AAVrhlO.
5. the viral vector is a lentiviral vector, or The viral vector is a retroviral vector. The pharmaceutical composition according to claim 3.
6. 6. The pharmaceutical composition of any one of claims 2 to 5, wherein the promoter is a pan-neuronal promoter, preferably wherein the pan-neuronal promoter is the synapsin I promoter; or wherein the promoter is a neuronal subtype-specific promoter, preferably wherein the neuronal subtype-specific promoter is the alpha-calcium / calmodulin kinase 2A promoter.
7. the Alzheimer's disease is sporadic Alzheimer's disease, or The Alzheimer's disease is late-onset or early-onset Alzheimer's disease. The pharmaceutical composition according to claim 1 or 2.
8. 10. The pharmaceutical composition of claim 2 or 7, which is in a vector, or is associated with or formulated for delivery by an exosome, or a lipid-based nanoparticle (LNP).
9. The polynucleotide of claim 8, wherein the polynucleotide is operably linked to a promoter; Preferably, the promoter is a pan-neuronal promoter, preferably the pan-neuronal promoter is the synapsin I promoter; or the promoter is a neuronal subtype specific promoter, preferably the neuronal subtype specific promoter is the alpha-calcium / calmodulin kinase 2A promoter. A pharmaceutical composition according to any one of claims 2, 7 and 8.
10. The pharmaceutical composition described in any one of claims 1 to 9, wherein the pharmaceutical composition is used so that the polypeptide, or the vector containing the polynucleotide, is administered to the CNS of the subject in need of treatment, preferably by intravenous delivery; intrathecal delivery; intracisternal delivery; intraventricular delivery; or stereotactic injection into a specific brain region, optionally into the cisterna magna, ventricle, lumbar spinal cavity; or direct injection into the hippocampus.
Citation Information
Patent Citations
Gene sequence and protein related to alzheimer's disease, and use thereof
JP2013107890A
Novel viral vector constructs for neuron-specific, optimized serial DOPA synthesis in vivo.
JP2013509890A
Adeno-associated virus-mediated gene transfer to the central nervous system
JP2016523835A
